News

Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers

AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer...

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable”...

Quipt Announces Execution of LOI To Acquire Leading Respiratory Supplier With Approximately $13 Million in Annualized Revenue and $1.6 Million in Net Income and Provides Outlook for 2022 Calendar End Run-rate of $180-$190 Million With $38-$43 Million in Adjusted EBITDA

error: Content is protected !!